title: Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.
abstract: BACKGROUND
  IDH (Isocitrate dehydrogenase) mutations occur frequently in gliomas, but their prognostic impact has not been fully assessed. We performed a meta-analysis of the association between IDH mutations and survival in gliomas.
  
  
  METHODS
  Pubmed and EMBASE databases were searched for studies reporting IDH mutations (IHD1/2 and IDH1) and survival in gliomas. The primary outcome was overall survival (OS); the secondary outcome was progression-free survival (PFS). Hazard ratios (HR) with 95% confidence interval (CI) were determined using the Mantel-Haenszel random-effect modeling. Funnel plot and Egger's test were conducted to examine the risk of publication bias.
  
  
  RESULTS
  Fifty-five studies (9487 patients) were included in the analysis. Fifty-four and twenty-seven studies investigated the association between IDH1/2 mutations and OS/PFS respectively in patients with glioma. The results showed that patients possessing an IDH1/2 mutation had significant advantages in OS (HR = 0.39, 95%CI: 0.34-0.45; P < 0.001) and PFS (HR = 0.42, 95% CI: 0.35-0.51; P < 0.001). Subgroup analysis showed a consistent result with pooled analysis, and patients with glioma of WHO grade III or II-III had better outcomes.
  
  
  CONCLUSIONS
  These findings provide further indication that patients with glioma harboring IDH mutations have improved OS and PFS, especially for patients with WHO grade III and grade II-III.
authors.affiliation: Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Xia
authors.affiliation: Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Wu
authors.affiliation: Shanghai Hospital of Integrated Traditional and Western Medicine, Hongkou District, Shanghai, China.
authors.forename: Zhiquan
authors.initials: Z
authors.lastname: Fu
authors.affiliation: Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Feng
authors.affiliation: Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
authors.forename: Enqi
authors.initials: E
authors.lastname: Qiao
authors.affiliation: Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
authors.forename: Qinglin
authors.initials: Q
authors.lastname: Li
authors.affiliation: Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
authors.forename: Caixing
authors.initials: C
authors.lastname: Sun
authors.affiliation: Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
authors.forename: Minghua
authors.initials: M
authors.lastname: Ge
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality; D018572:Disease-Free Survival; D005910:Glioma / Q000235:genetics* / Q000401:mortality; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D009154:Mutation; D064887:Observational Studies as Topic; D011379:Prognosis
chemical_list: C538784:IDH2 protein, human; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human
keywords: IDH mutations; glioma; prognosis